Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance

Metabolism: Clinical and Experimental

Volumn 53, Issue 6, 2004, Pages 777-781

  Anan, Futoshi ^a   Takahashi, Naohiko ^a   Ooie, Tatsuhiko ^a   Hara, Masahide ^a   Yoshimatsu, Hironobu ^a   Saikawa, Tetsunori ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN HEXETIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; BENZIMIDAZOLES; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; HEART RATE; HOMEOSTASIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; RECEPTORS, ANGIOTENSIN; REGRESSION ANALYSIS; TETRAZOLES;

EID: 3042732493     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.12.021     Document Type: Article

References (38)

1. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352
2. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566
3. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens. 5:1992;95-110
4. Gottdiener J.S., Reda D.J., Massie B.M., et al. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension Comparison of six antihypertensive agents. Circulation. 95:1997;2007-2014
5. Liebson P.R., Grandits G.A., Dianzumba S., et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 91:1995;698-706
6. Devereux R.B. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation. 95:1997;1983-1985
7. Schunkert H., Hense H.W., Muscholl M., et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 77:1997;24-31
8. Sadoshima J., Izumo S. Molecular characterization of angiotensin II - induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 73:1993;413-423
9. Urata H., Kinoshita A., Misono K.S., et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 265:1990;22348-22357
10. Goodfriend T.L., Elliott M.E., Catt K.J. Angiotensin receptors and their antagonists. N Engl J Med. 334:1996;1649-1654
11. Thurmann P.A., Kenedi P., Schmidt A., et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 98:1998;2037-2042
12. Swislocki A.L., Hoffman B.B., Reaven G.M. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens. 2:1989;419-423
13. Paolisso G., Tagliamonte M.R., Gambardella A., et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens. 11:1997;307-312
14. Iimura O., Shimamoto K., Matsuda K., et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens. 8:1995;353-357
15. World Health Organization. Arterial hypertension Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 628:1978;7-56
16. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy Comparison to necropsy findings. Am J Cardiol. 57:1986;450-458
17. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419
18. Malmqvist K., Kahan T., Edner M., et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 19:2001;1167-1176
19. Ikeda Y., Nakamura T., Takano H., et al. Angiotensin II-induced cardiomyocytes hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. J Lab Clin Med. 135:2000;353-359
20. Shikata C., Takeda A., Takeda N. Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy. Mol Cell Biochem. 248:2003;197-202
21. Seccia T.M., Belloni A.S., Kreutz R., et al. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol. 41:2003;666-673
22. Mitsunami K., Inoue S., Maeda K., et al. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther. 12:1998;469-474
23. Matsui T., Nagoshi T., Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle. 2:2003;220-223
24. Schluter K.D., Goldberg Y., Taimor G., et al. Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Cardiovasc Res. 40:1998;174-181
25. Yoshida K., Kohzuki M., Xu H.L., et al. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens. 19:2001;503-510
26. Grinsell J.W., Lardinois C.K., Swislocki A., et al. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens. 13:2000;370-375
27. Ghazzi M.N., Perez J.E., Antonucci T.K., et al. The Troglitazone Study Group. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439
28. Hirayama H., Sugano M., Abe M., et al. Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int J Cardiol. 77:2001;75-79
29. Folli F., Kahn C.R., Hansen H., et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest. 100:1997;2158-2169
30. Baron A.D., Steinberg H.O., Chaker H., et al. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 96:1995;786-792
31. de Bold A.J., Borenstein H.B., Veress A.T., et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28:1981;89-94
32. Kangawa K., Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun. 118:1984;131-139
33. Sudoh T., Kangawa K., Minamino N, et al. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81
34. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 92:1992;29-34
35. Kohno M., Fukui T., Horio T., et al. Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension. Am J Physiol. 266:1994;R451-R457
36. Kohno M., Minami M., Kano H., et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left ventricular hypertrophy. Metabolism. 49:2000;1356-1360
37. Anan F., Takahashi N., Ooie T., et al. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res. 26:2003;669-676
38. Rowe J.W., Young J.B., Minaker K.L., et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 30:1981;219-225